Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pavnell
- Ownership
- Private
- Development stage
- Other
01
Overview
Pavnell is a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company utilizes a proprietary drug discovery platform to identify highly selective modulators for historically challenging GPCR targets involved in pain, inflammation, and metabolic diseases. By leveraging structural biology and advanced screening techniques, Pavnell aims to create next-generation treatments with improved efficacy and reduced side-effect profiles. The company's current pipeline is in the pre-clinical stage, focusing on validating lead candidates for transition into clinical trials.
- Therapeutic areas
- ImmunologyNeurologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Pavnell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pavnell.